Ryufin

Azelis Group NV

Belgium · BE0974400328 · reports in EUR · Europe

The answers

From the annual report for the year to Dec 31, 2024. Each line says what it is based on.

Is it growing?Fair
Revenue +1.5% in the year to Dec 31, 2024, on the year before.
Is it a good business?Fair
It earned 6.3% on its shareholders' equity in the year to Dec 31, 2024.
Is it safe?Good
Equity is 51% of its assets, and operations brought in cash in the year.
Is the price fair?n/a
Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.

The year

Year to Dec 31, 2024, consolidated, in EUR.

€4.2B

revenue

9.2%

operating margin

€181M

net profit

Year by year

As filed; an earlier year can differ from its own report when the company restated it.

Dec 2021Dec 2022Dec 2023Dec 2024
Revenue€2.8B€4.1B€4.2B€4.2B
Operating profit€208M€388M€387M€386M
Net profit to shareholders€68M€213M€178M€181M
Earnings per share€0.29€0.91€0.74€0.74
Dividend per sharen/a€0.03n/a€0.22
Cash from operations€162M€369M€525M€323M
Cash€141M€268M€485M€304M
Total assets€4.0B€5.0B€5.6B€5.8B
Equity€2.3B€2.4B€2.7B€2.9B

What they do

In the company's own words, from the annual report.

distribution of specialty chemical products used in the Life Sciences (Personal Care, Home Care & Industrial Cleaning, Pharmaceuticals & Healthcare, Food & Nutrition, Animal Nutrition, and Agricultural & Environmental Solutions, and Flavors & Fragrances) and Industrial Chemicals industry (CASE, Advanced Materials & Additives, Lubricants & Metalworking Fluids, Electronics, Essentials and Fine Chemicals, and Textiles, Leather & Paper).

Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the answers and ratios from the filed figures.